Pharma Journalist -

Molecule discovery specialist X-Chem, proclaimed a remarkable extension of their present drug discovery collaboration with AstraZeneca. The agreement focuses on the synthesis and…
Read More...

Eiger Biopharmaceuticals displaying forte in development and commercialization of targeted therapies for rare diseases declared negative results for Phase 2 LIBERTY study in pulmonary…
Read More...

Marina Biotech, a biopharmaceutical company committed to the development and commercialization of advanced therapeutics for hypertension, arthritis, pain and oncology embarked on a…
Read More...

Digital patient decision support platform, WiserCare declared the appointment of Daniel J. Castillo as its Chief Executive Officer.  He brings with him profound experience and knowledge…
Read More...

A biotech company that designs and develops virus-based  immunotherapies, Transgene confirms dosing the first patient in  a Phase 1 Clinical Trial in China, evaluating T101, therapeutic…
Read More...

Ipsen bio-pharmaceuticals set to present five new sub-analyses of the pivotal Phase 3 NAPOLI-1 trial at this year's American Society of Clinical Oncology’s Gastrointestinal Cancer…
Read More...

US Food and Drug Administration (FDA) has assured priority review of Novartis supplemental Biological License Application (sBLA) for Kymriah suspension for intravenous infusion,…
Read More...

U.S FDA clears OBI Pharma's investigational new drug (IND) application for a Phase 1 study of a monoclonal antibody cancer immunotherapy targeting Globo H, a glycolipid antigen…
Read More...

BioLineRx, committed to oncology and immunology declared partial results from the monotherapy portion of BL-8040's Phase 2a COMBAT study. The study reveals that BL-8040 increases…
Read More...

Neurim Pahrmaceuticals and BIOCODEX undertake a license agreement that enlists the fact that BIOCODEX will possess the exclusive marketing rights to market Neurim's Rx paediatric…
Read More...